Phase II study of combination chemotherapy with biweekly cetuximab and irinotecan for wild-type KRAS metastatic colorectal cancer refractory to irinotecan, oxaliplatin, and fluoropyrimidines (Q82973963)
Jump to navigation
Jump to search
scientific article published on 22 December 2010
Language | Label | Description | Also known as |
---|---|---|---|
English | Phase II study of combination chemotherapy with biweekly cetuximab and irinotecan for wild-type KRAS metastatic colorectal cancer refractory to irinotecan, oxaliplatin, and fluoropyrimidines |
scientific article published on 22 December 2010 |
Statements
Phase II study of combination chemotherapy with biweekly cetuximab and irinotecan for wild-type KRAS metastatic colorectal cancer refractory to irinotecan, oxaliplatin, and fluoropyrimidines (English)
Kohei Shitara
Satoshi Yuki
Motoki Yoshida
Daisuke Takahari
Setsuo Utsunomiya
Tomoya Yokota
Yozo Sato
Yoshitaka Inaba
Masahiro Tajika
Hiroki Kawai
Hidekazu Yamaura
Mina Kato
Kentaro Yamazaki
Yoshito Komatsu
22 December 2010
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference